1

International Forum for Quality Cancer Care

Keble College, Oxford University, United Kingdom

September 8 – 9, 2018

FORUM PROGRAM

2

The International Forum for Quality Cancer Care (IFQCC) will provide a platform for interested parties and entities to collaborate in improving the quality and safety of cancer care across borders.

The Forum is organized by Cancer Care Commission, Oxford, UK, in collaboration with international leaders in health care delivery sciences and experts in oncology related disciplines.

Mission:

To provide a platform for exchange of knowledge and experience among individuals and entities interested in delivering quality cancer care.

Vision:

To become a world-leading forum in addressing cancer care delivery issues leading to a positive impact on the global efforts for cancer control.

Objectives:

1. Understand health systems and key reforms in cancer policy, with a

particular focus on value.

2. Share the experience of existing initiatives to improve quality of cancer care

at national levels and across borders.

3. Analyze positions of key stakeholders in relation to delivery of high quality

cancer care and their perceptions of the role of the healthcare industry in

responding to the challenge of cancer.

3

Welcome Message

We welcome you to the IFQCC 2018, held in Keble College, Oxford University. The event includes a two-day seminar with internationally renowned speakers and a Saturday night dinner in the famous College Hall.

The IFQCC 2018 is the Third Annual Meeting after meetings in 2016 and 2017 in Dubai, UAE and Beijing, China, respectively.

In this Forum, our international experts will tackle many relevant issues related to quality and safety of cancer care worldwide.

Participants will learn the best practices from the experts and colleagues who have done it before. We have more than 50 abstracts accepted to the Forum, of which, seven will be oral presentations and the remaining will be presented as posters.

We hope that you enjoy the rich environment of learning and interactions with colleagues in the attractive historical setting.

Prof. David Kerr Prof. Abdul Rahman Jazieh President, IFQCC 2018 Chairman, IFQCC 2018 Oxford University, UK Ministry of National Guard

Health Affairs, KSA

4

Scientific Committee Prof. David Kerr, University of Oxford, UK Prof. Abdul Rahman Jazieh, Ministry of National Guard Health Affairs, Saudi Arabia Prof. Rachel Kerr, University of Oxford, UK Organizing Committee Dr. Calum Kerr, UK Mr. Stewart Kerr, UK Ms. Ms. Debbie Stephenson, UK. Ms. Marie Gretchen Datario, KSA Abstract Management Team Ms. Nagham Sheblaq, KSA Dr. Ola Babelli, KSA Ms. Valerie Clark, USA In collaboration with Global Journal of Quality and Safety in Healthcare (www.jqsh.org)

5

International Forum for Quality Cancer Care (IFQCC 2018) Day 1- Saturday, September 8

08:00 – 09:00 Registration

09:00– 09:10 Welcoming Remarks

Session 1: Introduction Moderators: Mr. Calum Kerr

Time Topic Speaker

09:10 – 09:40 Global cancer burden and implications for health systems Prof. Michel Coleman

09:40 – 10:10 Can policy drive real improvements: the politicians view Miles Briggs MSP Shadow Cabinet Secretary, Health and Sport

10:10 – 10:25 Question and Answer All Session Speakers

10:25 - 10:45 BREAK

Session 2 Quality Initiatives Across borders Moderator: Prof. David Kerr

10:45 – 11:10 ASCO Quality Initiatives Dr. Clifford Hudis

11:10 – 11:35 NCCN and quality of care Dr. Robert Carlson

11:35 – 12:00 NHS and quality cancer care Prof. David Kerr

12:00 – 12:25 WHO Roles in QI of cancer care Prof. Ala Alwan

12:25 – 13:00 Round Table: Dissemination of Success All Session Speakers

13:00 – 13:55 Lunch and Poster viewing

Session 3 Improving Access to Medications Moderator: Dr. Clifford Hudis

13:55 – 14:20 The economics of innovative payment models for cancer drugs – we can do better

Prof Paula Lorgelly

14:20 – 14:45 New models to improve patient access to cancer drugs Gavin Lewis

14:45 – 15:10 Use of real time data on cancer drug usage Ashley Woolmore

15:10 – 15:20 Question and Answer All Session Speakers

15:20 – 15:50 BREAK and Poster Viewing, GROUP PHOTO

Session 4 Oral Presentation of Selected Abstracts Moderator: Prof. AR Jazieh

15:50 – 16:00 A novel, web-based intervention to reduce cancer treatment-related financial distress: a randomized controlled pilot study

George Tran, USA

16:00 – 16:10 Engaging Partners for Provision of Access to Anti-Cancer Medicines In A Resource Constrained Country: A Success Story

Jamil Abid, Pakistan

16:10 – 16:20 Suspected cancer program (SCP): Toward an efficient and timely care for suspected cancer cases!

Mohammed Algarni, Saudi Arabia

16:20 – 16:30 Continuous intravenous or subcutaneous infusion of high Wu Lige, China

6

dose morphine for refractory pain control in advanced cancer patients

16:30 – 16:40 Concordance of Cancer Moonshot artificial intelligence platform, for cancer treatment decisions and recommendations in comparison with Oncologists/Tumour board – For 60 breast cancer cases

Deva Reddy, India

16:40 – 16:50 Overcoming appointment delay in radiotherapy: a single institution experience.

Mohammed Ait Erraise, Morocco

16:50 – 17:00 Improving utilization of PET/CT for cancer patients: A Choose Wisely Project!

Ashwaq Al Olayan, Saudi Arabia

End of abstract Presentation

17:00-18:00 Round Table: Sustaining therapeutic innovation – health systems response Moderator: Prof. David Kerr Panelists: Dr. Bob Carlson; Prof. Alex Eniu; Dr. Gavin Lewis

1800 Adjourn

7

International Forum for Quality Cancer Care (IFQCC 2018) Day 2 – Sunday, September 9

8:00 – 8:30 Registration

Time Topic Speaker

Session 5: Drivers of Quality Improvement: Moderator: Prof. David Kerr

0900 – 9:20 Can accreditation drive up quality – the NHS experience?

Dr. John Graham

9:20 – 9:45 Does the Press have a role in improving health standards?

Ms. Pennie Taylor

09:40-09:55 Question and Answer All Session Speakers

09:55-10:10 Announcement of Best Abstract Winners

10:10- 10:20 BREAK Session 6 Value Driven Cancer Care

Moderator: Prof. AR Jazieh

10:20-10:45 NCCN Approach Dr. Robert Carlson

10:45-11:10 European perspectives on Value Driven Cancer Care Dr. Alex Eniu

11:10-11:35 Can we truly identify and eliminate ‘waste’ or inappropriate resource usage in cancer care?

Sir Muir Gray

11:35 – 12:45 Round Table: What is Value in Cancer Care? All Session Speakers

12:45 – 13:30 Lunch

Session 7 How to deliver a Quality Improvement Program? Moderators: Dr. Robert Carlson

13:30 – 13:55 How to selects measures and indicators Dr. Tricia Woodhead

13:55 – 14:20 Cancer Care Commission Program to advance quality Mr. Calum Kerr

14:20 – 14:45 Publishing Quality Improvement Projects Prof. AR Jazieh

14:45 – 15:00 Panel All Session Speakers

15:10- 15:30 BREAK

Session 8 Open Forum: Implementing Value Driven Cancer Care: Challenges and Solutions Moderator: Mr. Calum Kerr

15:30-15:50 Personalized medicine in cancer management: Experience from Saudi Arabia

Dr. Jamal Zekri

15:50-16:10 Improving access to cancer care: Beijing and Wuhan Experience

Dr. Fred Sun

16:10-16:30 Improving access to cancer care at scale Dr. Dinesh Pendharkar

1630 Evaluation/Certificate/Adjourn

8

List of Accepted Abstracts

ORAL PRESENTATIONS

1. A novel, web-based intervention to reduce cancer treatment-related financial distress: a randomized controlled pilot study Authors: 1George Tran, 2Jonathan Nicolla, 2Fred Friedman, 3Gregory Samsa, 4Peter Ubel, 5Kathryn Pollak, 1-2-6Yousuf Zafar 1Duke University, School of Medicine, Durham, USA, 2Duke Cancer institute, Durham, USA 3Duke University, Department of Bioinformatics and Biostatistics, Durham, USA, 4Duke University, Fuqua School of Business, Durham, USA, 5Duke University School of Medicine, Department of Community and Family Medicine, Durham, USA, 6Sanford School of Public Policy, Durham, USA

2. Engaging Partners For Provision of Access to Anti-Cancer Medicines In A

Resource Constrained Country: A Success Story Authors: 1Abid Jameel, 1Sadaf Chiragh. 1Hayatabad Medical Complex, Peshawar, Pakistan

3. Suspected cancer program (SCP): Toward an efficient and timely care for suspected cancer Authors: Mohammed Algarni, Ashwaq Al Olayan, Fahad Azzumea, Abdul Rahman Jazieh King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia

4. Continuous intravenous or subcutaneous infusion of high dose morphine for refractory pain control in advanced cancer patients Authors: 1Wu Lige, 1Wang Guohua 1The Second Hospital of Wuhan Iron and Steel (Group) Corp., Wuhan, China

5. Concordance of Cancer Moonshot artificial intelligence platform, for cancer treatment decisions and recommendations in comparison with Oncologists/Tumour board – For 60 breast cancer cases Authors:

1Deva Reddy, 2Reddy Ram, 1Reddy Sayukta 1Cancer Moonshot, Bangalore, India, 2Care Cancer Hospital, Hyderabad, India

9

6. Overcoming appointment delay in radiotherapy : a single institution experience Authors: 1Mohammed Ait Erraisse, 1Ouafae Masbah, 1Touria Bouhafa, 1Khalid Hassouni 1University Hospital Hassan II, Fez, Morocco

7. Improving utilization of PET/CT for cancer patients: A Choose Wisely Project! Authors: 1Ashwaq Al Olayan, 1Ghulam Syed, 1Mona Alshami, 1Khadega Abdulgasim, 1Nour Ibrahim, 1Salem Alshehri, 1Nashmia Almutairi, 1Saadia Ur-razzaq, 1Abdul Rahman Jazieh 1King Abdulaziz Medical City, MNGHA, Riyadh, Saudi Arabia

10

POSTER PRESENTATIONS

8. The negative impact of media on quality of cancer care Authors: 1Safaa Al-Zeidaneen, 2Ali Al-Ebuos 1Institution Al-Balqa Applied University, Zarqa, Jordan, 2King Hussein Medical Center, Amman, Jordan

9. Reducing central line-associated bloodstream infections among hematology patients at the Ministry of National Guard-Health Affairs, Riyad Authors: 1Khadega A Abuelgasim, 1Mona Alshami, 1Andrea Doherty, 1Kholoud AlAmeer, 1Ziad Alzahrani, 1Yahya Bakheet, 1Malia Ravestijn, 1Emelin Anfone, 1Allyn Alfeche, 1Erlinda Osmillo, 1Tayseer Mostafa, 1Mohsen Alzahrani, 1Hanan Edrees 1King Abdulaziz Medical City, MNGHA, Riyadh, Saudi Arabia

10. Granulocyte Colony Stimulating Factor and febrile neutropenia in patients receiving docetaxel based chemotherapy for breast cancer Authors: 1-2Jamal Zekri, 1Azhar Nawaz, 1Haleem Rasool, 1Imran Ahmad, 1Hossam Abdel Rahman, 1Reyad Dada, 3Ehab Mosaad Abdelghany, 4Kamel Farag, 5Refaei Belal Ibrahim, 1Mohamed Youssef Deibas, 5Mohamed Kamal Kamel, 1Ahmad Allithy 1King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia, 2Al-Faisal University, Riyadh, Saudi Arabia, 3National Cancer Institute, Cairo, Egypt, 4Faculty of Medicine Mansoura University, Mansoura, Egypt, 5Faculty of Medicine Al- Azhar University, Cairo, Egypt

11. Measuring the quality of life among cancer outpatient at King Abdulaziz Medical City, Riyadh, Saudi Arabia Authors: 1Abdullah Algarni, 1Sultan Alshehri, 1Riyadh Alghamdi, 1Abdulrhman Alzamil, 1Rayan Alturki, 1Mohammed Almutairi, 1Humoud Alhoraim, 1Emad Masuadi 1King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

12. The Impact of International Accreditation in Improving the Quality of Cancer Care: Our experience with ASCO-QOPI Authors: 1Nafisa Abdelhafeez, 1Ziad AlZahrani, 1Mona Alshami, 1Mohammed Alkaiyat, 1Tabrez Pasha, 1Haytham Hamdan, 1Abdul Rahman Jazieh 1King Abdulaziz Medical City, MNGHA, Riyadh, Saudi Arabia

11

13. Results of a validation study: Is Idylla a reliable technology to detect RAS

mutation in colorectal cancer tissue? Authors: 1-2Jamal Zekri, 2Mohammed Baghdadi, 3Hamoud Khallaf, 2Hosam Alardati 1Al Faisal University, Riyadh, Saudi Arabia, 2King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia, 3King Fahad Specialist Hospital, Dammam, Saudi Arabia

14. Oncotype-DX Assay and PREDICT tool in Guiding Decisions of Adjuvant Chemotherapy in Early Breast Cancer Authors: 1-2Jamal Zekri, 1Maaz Alata, 3Reem Zabani 1King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia, 2Al-Faisal University, Riyadh, Saudi Arabia, 3Ibn Sina National Medical College, Jeddah, Saudi Arabia.

15. Identifying Potential Therapeutic Targets in Her2 Over-expressed Breast Cancer Authors: 1-2Jamal Zekri, 2Mohammed Baghdadi, 2Turki Sobahy, 2Hossam Alardati 1Al Faisal University, Riyadh, Saudi Arabia, 2King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia

16. Bone modifying agent in the treatment of bone metastases in patients with metastatic breast cancer: Real-life practice Authors: 1Kamel Farag, 2-3Jamal Zekri, 3Osama Yousof, 4Yazeed Zabani, 5Wael Mohammed, 6Amal Abdulwahab, 7Gomaa Abdelfattah Ahmed 1Institution Mansoura University, Mansoura, Egypt, 2Al Faisal University, Riyadh, Saudi Arabia 3King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia, 4National Cancer Institute, Cairo, Egypt, 5King Saud bin Abdul-Aziz University for Health Sciences, Jeddah, Saudi Arabia, 6Port Said University, Port Said, Egypt, 7King Abdullah Medical City, Jeddah, Saudi Arabia 8Beni Suef University, Beni Suef, Egypt

17. PICC line related venous thrombosis in Medical oncology: A single centre experience Authors: 1Syed Azhar Javed Rizvi, 1SM Reza, 1Manar Almusarhed, 1Osamah Al-Asadi, 1Hany Eldeeb, 1Maria Karina, 1 Wasiru Saka 1Milton Keynes University Hospital, Milton Keynes, United Kingdom

12

18. Beijing Yanhua Hospital Carried out International Multidisciplinary Treatment (MDT) Author: Zhang Qing Chun Beijing Yanhua Hospital, Beijing, China

19. Relationship between Expression of β-tubulin-III plus ERCC1 in Advanced Ovian Cancer and Chemotherapy Sensitivity of Palitaxel plus platin Chemotherpy Authors:

1Yufei Fan, 1Yonghua Hu, 1Dinggang Li, 2David Kerr 1Beijing Yanhua Hospital, Beijing, China, 2Oxford University, London, UK

20. Access to Erythropoiesis - stimulating agent (ESA) and transfusion in chemotherapy-induced anaemia: the experience of Medical Oncology Department of Hassan II University Hospital Center of fez Authors: Bouchra Abou El Jaoud, Zineb Benbrahim, Hanae Bedoudou, Karima Oualla, Lamiae Amaadour, Samia Arifi, Naoufel Mellas Hassan II University Hospital Center, Fez, Morocco

21. Access to targeted therapy in metastatic renal cell carcinoma patients in Morocco Authors: Mariam Benhami, Zineb Benbrahim, Lamiae Amaadou, Karima Oualla, Samia Arifi, Naoufal Mellas Hassan II University Hospital Center, Fez, Morocco

22. Efficacy and toxicity of target therapy in metastatic renal cell carcinoma at Department of medical oncology Fez Authors: Mariam Benhami, Zineb Benbrahim, Lamiae Amaadou, Karima Oualla, Samia Arifi, Naoufal Mellas Medical Oncology Department of the Hassan II University Hospital Center, Fez, Morocco

23. Palliative care in Egypt: the experience of the Gharbiah Cancer Society Authors: Mohamed Hablas. Gharbia Cancer Society, Tanta, Egypt

24. Multidisciplinary tumor board in oncology : A single institution experience Authors: Mohammed Ait Erraise, Touria Bouhafa, Khalid Hassouni University Hospital Hassan II, Fex, Morocco

13

25. Screening for cervical cancer in Morocco: through a mass screening campaign in the Rhamnas region Authors: 1Mohammed Ait Erraisse, 2Mohamed Amine Benhmidoune, 3Najib Derhem, 2Ali Tahri, 2Najib Bouras 1University Hospital Hassan II, Fez, Morocco, 2Private Oncology Clinic, Marrakech, Morocco 3Private Oncology Clinic, Agadir, Morocco

26. Multidisciplinary Tumour Boards: Our Local Experience

Authors: 1-2Rahma Djouabi, 1-2Chouaib Hellal, 1-2Assia Bensalem 1Hospital Establishment DIDOUCHE MOURAD, Constantine, Algeria, 2University Salah Boubnider, Constantine, Algeria.

27. Nipple Sparing Mastectomy, Our Experience with Outcomes and

Complications Authors: 1Hiba Rauf, 1Muhammad Rauf Shaikh, 2Maha Rauf, 1Noshad Shaikh, 1Fatima Rawish 1Dow Medical College, Karachi, Pakistan, 2University of Waterloo, Waterloo, Canada

28. Prostate cancer: patients’ Quality of life Authors: 1Soumia Berrad, 1Zineb Benbrahim, 1Hayat Erraichi, 1Karima Oualla, 1Samia Arifi, 1Naoufal Mellas

1 Hassan II University Hospital, Fez, Morocco

29. Improving boarding time for patients in Emergency Department (ED) Authors: Faisal Farooqui, Ali Al Khathami, Andrea E. Doherty, Tabrez Pasha, Ashwaq Al Olayan, Ayman Hejazi, Abdullah Al Qarni, Mohsen Al Zahrani, Faisal Al Safi, Abdul Rahman Jazieh King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh

30. Optimization of clinic management to reduce walk-ins Authors: Faisal Farooqui, Nashmia Al Mutairi, Faisal Al Safi, Tabrez Pasha, Abdul Rahman Jazieh King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia

14

31. Enhancing timely response of physicians to Critical Laboratory Values Authors: Faisal Farooqui, Ashwaq Al Olayan, Mohsen Al Zahrani, Abdullah Al Qarni, Nashmia Al Mutairi, Tabrez Pasha, Abdulaziz Zaben, Abdul Rahman Jazieh King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia

32. Impact of effective Communication Among In-patient Palliative Care

Providers Authors: Faisal Farooqui, Abdullah Al Qarni, Ahmed Bin Ahmed, Tabrez Pasha, Abdul Rahman Jazieh King Abdulaziz Medical City, Ministry of National of Health Affairs, Riyadh, Saudi Arabia

33. Prediction of lung metastases and Recognizing MicroRNAs (miR-210) as novel a cancer prognosis biomarker using Radio-Genomics in Soft-tissue sarcomas for precision medicine Authors: 1Deva Reddy, 2Reddy Ram, 1Reddy Sayukta 1Cancer Moonshot, Bangalore, India, 2Care Cancer Hospital, Hyderabad, India

34. Predicting Drug Response in Cancer in Cancer Cell Lines using Deep Learning for precision treatments Authors: 1Deva Reddy, 2Reddy Ram, 1Reddy Sayukta 1Cancer Moonshot, Bangalore, India, 2Care Cancer Hospital, Hyderabad, India

35. Quality of life and sexuality of women with breast cancer: impact of mastectomy Authors: Meryem Azegrar, Zineb Benbrahim, Lamiae Amadour, Karima Oualla, Samia Arifi, Naoufal Mellas University Hospital Hassan II, Fez, Morocco

36. Adherence to Capecitabine among patients with gastro-intestinal and breast cancers Authors: Meryem Azegrar, Zineb Benbrahim, Lamiae Amadour, Karima Oualla, Samia Arifi, Naoufal Mellas. University Hospital Hassan II, Fez, Morocco

15

37. Impact of persistent pain after mastectomy in patients treated for breast cancer Authors: Mermey Azegrar, Zineb Benbrahim, Lamiae Amadour, Karima Oualla, Samia Arifi, Naoufal Mellas University Hospital Hassan II, Fez, Morocco

38. Quality of Life Evaluation of Algerian Patients Under Platinum Based Chemotherapy Authors: 1-2Mohamed Aimene Melzi, 1Zoubir Derbouz, 1-2Adda Bounedjar 1University Hospital Frantz Fanon of Blida, Blida, Algeria, 2University Saad DAHLEB of Blida, Blida, Algeria

39. Effectiveness of Multimodal Combination of KIDNET, Hope and Positive Psychotherapy in Children with Cancers: Experiences from a Super-Specialty Centre Pilot Study Authors: Maheswar Satpathy University College London, London, UK

40. Prognostic Factors for Hormone Sensitive Metastatic Prostate Cancer:Impact of Disease Volume Authors: 1Alhanafy Alshimaa, 1Fouad Zanaty, 1Reda Ibrahem, 1Suzan Omar 1Menoufia University, Sheben Elkom, Egypt

41. Transformation of enteral nutritional supplements into oral nutritional supplements Authors: Khaoula Mazouzi, Amira Mamine Public Hospital of Souk Ahras, Souk Ahras, Algeria

42. Improvement of organoleptic properties of enteral nutritional supplements and their transformation into oral supplements: A feasibility study Authors: Khaoula Mazouzi, Amira Mamine Public Hospital of Souk Ahras, Souk Ahras, Algeria

43. Identifying gaps in care by monitoring adherence to guidelines Authors: Ahmed Mohamed Hashim, Ashwaq Al Olayan King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, KSA

16

44. Oncology Nurse Specialists – Can the value of this role be measured, welcomed and accepted in Saudi Arabia? Authors: Angela Fitzgerald-Smith, Andrea Doherty, Ashwaq Al Olayan, Mohammed Al Harbi, Ahmed Al Qudimat King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, KSA

45. Evaluation of the Multidisciplinary Consensus Meeting (MCP) in the Gastro-

intestinal Oncology Authors: Y. El Ouai, Z. Benbraim, N Lahmidani, A Ibrahimi, N. Mellas Hassan II University Hospital, Fez, Morocco

46. Access to bone modulating agents for patients with metastatic lung cancer:

experience of the Medical Oncology Department of Hassan II University Hospital, Fez Authors: R.El hazzaz, Z.Benbrahim, L.Hajjane, L.Nouiakh,FZ.El m’rabet, N.Acherfi, S.Arifi, N.Mellas Hassan II University Hospital, Fez, Morocco

47. Well-being in cancer patients' end of life: impact of spirituality: About 10

cases Authors: Lamyae Nouiakh, Zineb Benbrahim, Karima Oualla, Reda El Hazzaz, Soumia Berrad, Hayat Erraichi, Lamiae Amaadour, Samia Arifi, Mellas Nawfal Hassan II Hospital, Fez, Morocco

48. Surviving Bone Marrow Transplantation Program During War Time In Syria Authors: 1Mhd Nabeel Rajeh, 2Zahera Fahed, 3Maha Manachi, 4Seham Suliman, 5Mohammed Kelta 1Saint Louis University, Saint Louis, USA, 2Private Practice, Damascus, Syria, 3Albiruni University Hospital, Damascus, Syria, 4Damascus University, Damascus, Syria, 5Christ Hospital, Chicago, USA

49. Quality assurance in conducting a pilot mass screening of colorectal cancer in Algeria Authors: 1Chahira Mazouzi, 2Kamel Bouzid, 1Myriem Belloul, 1Farid Aroun, 1Ahmed Salah 1University Abderrahmane Mira CHU Béjaia, Algeria, 2EHS P & M CURIE Center, Algiers, Algeria

17

50. Use of Hematopoetic growth factors in medical oncology Authors: A. Bahouli, S. Messioud, C. Hellal, A. Bensalem Medical Oncology Department, DIDOUCHE Mourad Hospital, Faculty of Medicine, University 3, Constantine, Algeria.

51. Improving access to cancer care at scale Authors: Dinesh Pendharkar Sarvodaya Hospital, Delhi, India

52. An examination of quality of life and unmet supportive care needs in survivors of adult haematological malignancies Authors: 1A. Immanuel, 1J. Hunt. 1E. van Teijlingen, 2H. McCarthy 1Bournermouth University, Dorset, UK 2Royal Bournermouth Hospital, Dorset, UK All accepted abstracts published in a conference proceeding in the Global Journal on Quality and Safety in Healthcare (http://www.jqsh.org/aheadofprint.asp) (http://www.jqsh.org/temp/GlobJQualSafHealthc000-9833464_024353.pdf)

www.jqsh.org

18

FACULTY PROFILE

Dr Ala Alwan is the WHO Regional Director for the Eastern Mediterranean from 1 February 2012. He was Assistant Director-General for Noncommunicable Diseases and Mental Health from February 2008 to February 2012. Dr Alwan graduated in Medicine from the University of Alexandria. He practiced medicine in Scotland and obtained his postgraduate training and qualifications in the United Kingdom. Following his return to Iraq, his home country, he held several positions in clinical and academic medicine and public health. He was Professor and Dean of the Faculty of Medicine, Mustansiriya University, Baghdad. In 1992, he joined WHO as Regional Adviser for

Noncommunicable Diseases in the Regional Office for the Eastern Mediterranean. He then served as WHO Representative in Oman, and Director, Division of Health Systems Development in the Eastern Mediterranean Region. In 1998, Dr Alwan was reassigned to WHO headquarters as Director for Noncommunicable Diseases Prevention and then Director of the Department of Noncommunicable Diseases Management. In 2001, he became WHO Representative in Jordan. From 2003 to 2005, he was Minister of Education and Minister of Health in the Government of Iraq. From 2005 to January 2008, he was Representative of the Director-General and Assistant Director-General for Health Action in Crises.

Miles Briggs is the Shadow Cabinet Secretary for Health and Sport and a Member of the Parliament’s Health and Sport Committee. He was previously the Shadow Minister for Mental & Public Health. Miles is Co-Convenor of the Parliament’s Cross Party Group on Cancer and Convenor of the Parliament’s Cross Party Group on Scottish Horseracing & Bloodstock Industries. He is actively involved in numerous Cross Party Groups.

Educated at Auchtergaven Primary School and Perth Grammar School, Miles then attended Robert Gordon University in Aberdeen where he studied Management & Politics. Following graduation, Miles worked for The Executive Council of the Province of Prince Edward Island, Canada. He then spent 10 years working as a

19

Political Adviser to MSPs Dr. Nanette Milne and Liz Smith. Outside of politics Miles is a keen hill walker, having completed 83 Munros to dates, and is also interested in rugby, countryside issues, photography, Scottish history & music.

Robert W. Carlson, MD, is the Chief Executive Officer at the National Comprehensive Cancer Network (NCCN). He joined NCCN as CEO in January 2013 following an esteemed history of leadership positions within the organization including, most notably, Representative to the NCCN Board of Directors, Chair of the Breast Cancer Guidelines Panel, Member and Founding Chair of the Breast Cancer Risk Reduction Guidelines Panel, and Chair of the Survivorship Guidelines Panel. Prior to his appointment as CEO at NCCN, Dr. Carlson served

as Professor of Medicine in the Division of Oncology and Stanford Medical Informatics at Stanford University Medical Center, as well as Medical Director of Inpatient Oncology and Hematology at Stanford Cancer Institute in California. Dr. Carlson is a graduate of Stanford University Medical School and he completed his internship and junior residency in internal medicine at Barnes Hospital Group in St. Louis before returning to Stanford University to complete his senior residency. He earned a Bachelor of Science with distinction from Stanford University, specializing in biological sciences. Dr. Carlson is board certified in Medical Oncology and Internal Medicine.

Prof. Michel Coleman Since 1995, he has been Professor of Epidemiology and Vital Statistics at the London School of Hygiene & Tropical Medicine. He was Deputy Chief Medical Statistician at the Office for National Statistics from 1995 to 2004 and Head of the Cancer and Public Health Unit at the School from 1998 to 2003. He has previously worked for the World Health Organisation at the International Agency for Research on Cancer in Lyon (1987-1991), and was Medical Director of the Thames Cancer Registry in London (1991-1995). His main interests include trends and inequalities in cancer incidence,

mortality and survival, and the application of these metrics to public health policy and cancer control.

20

Dr. Alexandru Eniu is a senior medical oncologist in the Department of Breast tumours at the Cancer Institute "Ion Chiricuta" in Cluj-Napoca, Romania. He holds both the MD and PhD degree in Medical Sciences from the University of Medicine “Iuliu Hatieganu” in Cluj-Napoca. Dr. Eniu has an extensive experience from visits abroad. He was awarded a Mayo Foundation Visiting Clinician Scholarship at the Mayo Breast Cancer Clinic in Jacksonville, Florida and has been a visiting clinician at the MD Anderson

Cancer Center in Houston, Texas and the Memorial Sloan Kettering Cancer Center in New York. He did a fellowship at the European Institute of Oncology in Milan. As an active member of both national and international societies, Alexandru Eniu holds positions in various committees. Within ESO, he is currently serving as coordinator for the ESO Eastern Europe and Balkan Region Program. He is the chair of the ESMO Global Policy Committee and, since 2014, he was invited to join the ESMO Executive Board, leading several initiatives tackling disparities in cancer outcomes across Europe and the world. Within ASCO, he served as chairman of the ASCO International Affairs Committee. Furthermore, he is a member of the editorial board of several oncology journals including Annals of Oncology. He participated in the process of developing international and national guidelines for the management of cancer patients, serving as the Co-Chair of the Treatment and Allocation of resources Panel of the Breast Health Global Initiative and as panel member of the Advanced Breast Cancer (ABC3 and ABC4) International Consensus Conference. He wrote 4 book chapters and more than 80 articles in international peer reviewed journals within his specialty breast cancer.

Sir Muir Gray has worked for the National Health Service in England since 1972, occupying a variety of senior positions during that time, including serving as the Director of Research and Development for Anglia and Oxford Regional Health Authority, and first establishing and then being the Director of the UK National Screening Committee. He founded the National Library for Health, and was the Director of Clinical Knowledge, Process, and Safety for the NHS (England) National Programme for IT, serving as the

Director of the National Knowledge Service. He was the first person to hold the post of Chief Knowledge Officer of the NHS (England), also serving as the co-Director of the Department of Health’s Quality Innovation Productivity and Prevention (QIPP) Right Care Programme. Together with Sir Iain Chalmers, Muir was instrumental in establishing the Cochrane Collaboration.

21

Sir Muir is an internationally renowned authority on healthcare systems and has advised governments of several countries outside the UK including Australia, New Zealand, Italy, Spain and Germany.

Sir Muir is also a Visiting Professor in the Nuffield Department of Surgical Sciences at the University of Oxford. He received the CBE in 2000 and was knighted in 2005 for services to the National Health Service.

Sir Muir is working on the Value Based Healthcare theme within the Nuffield Department of Primary Care Health Sciences and is interested in understanding and implementing value based healthcare, particularly focusing on the Triple Value framework:

Allocative value, determined by how the assets are distributed to different sub groups in the population

Technical value, determined by how well resources are used for all the people in need in each sub group

Personal value, determined by how well the decision relates to the values of each individual

Dr. Clifford Hudis, MD, FACP, FASCO is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the CEO of its Conquer Cancer Foundation and the Chairman of the Board of Governors of ASCO’s CancerLinQ. Dr. Hudis previously served in a variety of roles at ASCO, including as President during the Society’s 50th anniversary year (2013-14). Before transitioning full-time to ASCO, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City, where he was also Professor of Medicine at the Weill Medical College of Cornell

University. In this role, he developed more effective treatments for all stages of breast cancer, while also exploring novel prevention opportunities. As CEO of ASCO, Dr. Hudis’ focus is on education, research and promotion of the highest quality of care by the Society’s nearly 45,000 members. Key initiatives include the acceleration of CancerLinQ, ASCO’s focused effort to increase insights and learning from the rapidly accumulating electronic records of routine care provided by clinicians. Dr. Hudis is a consultant medical oncologist with a clinical practice limited to the treatment of people with breast cancer.

22

Prof. Abdulrahman Jazieh is the Chairman, Department of Oncology, King Abdulaziz Medical City and a Professor at King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. Dr. Jazieh is the founding Editor-In-Chief of the Global Journal of Quality and Safety in Health Care. He obtained his MD Degree from Damascus University, Syria and his

Masters in Public Health from Tulane University, New Orleans. He completed his Fellowship in Hematology and Medical Oncology from University of Arkansas for Medical Sciences, Arkansas. He has American Boards of Internal Medicine, Hematology and Medical Oncology. He was a Professor of Medicine and Director of Hematology Oncology Division at University of Cincinnati. Dr. Jazieh is a member of multiple US Professional society. He is the Chairman of the International Affairs Committee of ASCO Dr. Jazieh won multiple honors and awards including proclamation to the City of Cincinnati naming the day of January 5, 2006 as Dr. Abdul Rahman Jazieh Day.

Prof. David Kerr Chief Research Advisor, SIDRA Director, Qatar Biomedical Research Institute Member of Supreme Council of Health Professor of Cancer Medicine, University of Oxford Professor of Medicine, Weill Cornell Medical College David Kerr has been given a 5 year leave of absence from the University of Oxford to become the Chief Scientist for SIDRA, an academic Health Science Centre (www.sidra.org)

endowed with $ 8 billion, and Director of Qatar’s national Biomedical Research Institute. From there, he plans to build a collaborative biomedical research network through the Middle East and contribute to improving Global Health. He has been appointed to the Supreme Council of Health, effectively Qatar’s Health cabinet, practises medicine in the Al Amal Cancer Hospital and contributes to Oxford as Professor of Cancer Medicine where he has worked with colleagues to build a new Institute for Cancer Medicine and Cancer Hospital. He has an international reputation for the treatment of and research into colorectal cancer, and is developing new approaches to cancer treatment which involve novel biomarkers and inhibitors of key biochemical pathways. The quality of his work has been recognised by the award of several international prizes and the first NHS Nye-Bevan

23

award for innovation. He has published more than 350 articles in peer-reviewed journals (including New England Journal of Medicine, Lancet, Nature Genetics) and has contributed to many books on cancer. David has made a significant contribution to reforming the NHS as a Founding Commissioner for Health Improvement; Chair of the National Cancer Services Collaborative, Instigator of the Department of Health’s networked approach to clinical cancer research and developed a 20 year plan for the future of the NHS in Scotland, the “Kerr Report”. He was Editor-in-Chief of Annals of Oncology, Europe’s premier medical oncology journal Reviews Oncology (2001-2008), and is on the editorial board of several other journals. He has established a series of major international collaborations, building a trials network with India’s leading cancer centres INDOX (http://www.indox.org.uk/) and AfrOx (http://www.afrox.org), which aims to improve the delivery of cancer care in Sub Saharan Africa. He was elected Fellow of the Academy of Medical Sciences in 2000, Honorary Fellow of Royal College of General Practitioners in 2007, appointed Commander of the British Empire in 2002 and was recently appointed President of the European Society of Medical Oncology.

Calum Kerr, MBA, BSc, CMP

Calum is a co-founder and Executive Director of Cancer Care Commission, Oxford.

NHS UK Healthcare Executive with 30+ years experience of senior operational leadership and strategic design and implementation , Calum has fulfilled a number of high profile roles in NHS UK, and led the Service Redesign Team for a national healthcare organization ,which shaped and implemented its strategic direction. His expertise includes strategic planning, operational modelling, leadership, managing change and

organizational culture.

Experience in working closely with UK & Scottish Government Health Departments, including high profile Ministerial visits to Botswana, South Africa and Zimbabwe providing consultation and support on organizational development and operational policies and procedures.

Calum has a particular interest and expertise in organisational development, change management, continuous quality improvement and leadership at the strategic and individual level. He is an experienced executive coach and change agent.

With a Bachelor’s degree in Psychology and a Master’s degree in Business, Calum is completing his Doctorate in Management and Leadership, which combined with

24

extensive operational experience, provide a sound base to approach any development issue.

He was the First National (UK) adviser to the Royal College of Surgeons on Pre-hospital Care and is a College lecturer in Business Studies and Organisational Psychology.

Gavin Lewis: originally was an undergraduate in Economics and Politics, before working for the Scottish Government as an Economist in the Health Department. After obtaining an MSc in Health Economics from York University, he joined the Pharmaceutical industry for Roche in the UK where he worked for over 10 years developing and leading their Health Economics and Pricing department. He has experience in leading over 50 Health Technology appraisals with NICE, SMC and also prepared Roche’s response to the Value Based

Pricing consultation and contributed to the development of the NICE Guide to Methods for Technology Appraisal. In 2012 Gavin transferred to Basel to start a new role for the company as Head of Pricing and Market Access for Region Europe, where he has developed a new team with responsibilities for strategic pricing, payer marketing and real world evidence for Europe.

Dr John Graham was the Director of the National Collaborating Centre for Cancer (NCC-C) from 2009 to 2016 which produced cancer guidelines for the National Institute of Health & Care Excellence (NICE). From 2016 to 2018 he worked 2 days a week as a clinical advisor for the National Guideline Alliance, a new merged body that is contracted to produce most of NICE’s cancer guidelines He also works as a consultant clinical oncologist in south-west England specialising in breast and urological cancers. In addition to his guideline work with NCC-C & NGA, John was vice-chair of one of NICE’s

guideline updates committees, has been an expert advisor to NICE’s Technology Appraisal process for new cancer drugs and to NICE’s Diagnostics Assessment Programme. John Graham trained in oncology in Glasgow and London. He has worked as a consultant in academic oncology centres in Bristol and Glasgow and has experience of phase I, II & III clinical trials in oncology. In 2007 he moved to Somerset in south-

25

west England to set up a new cancer centre that opened in 2009. Since 2009 he has worked part-time for NICE’s clinical guidelines programme and part-time treating cancer patients in Somerset. He is a member of the Somerset Wiltshire Avon & Gloucester Cancer Alliance and Lead Clinician for Taunton & Somerset NHS Foundation Trust.

Paula Lorgelly, Deputy Director & Director of Consulting

Paula joins OHE from the Centre for Health Economics (CHE), Monash University, Australia. During her time at CHE, Paula worked on public health / policy related research, supervised PhD students including being CHE PhD Program Director, and continued her work on wellbeing measures. She was a standing member of the Economics Sub-Committee of the Pharmaceutical Benefits

Advisory Committee, and in this capacity provided advice on the effectiveness and cost effectiveness of treatments seeking reimbursement on the Pharmaceutical Benefits Scheme in Australia.

Paula has over 15 years’ experience working in academia in Australia and the United Kingdom. Her research spans three key areas of health economics: the determinants of health, economic evaluation and outcome measurement. She is currently working in the clinical areas of oncology, including genomic testing; maternal mental health; HIV; and workplace health promotion. During her career Paula has developed expertise in:

Econometric analyses of panel data and cross-sectional survey data, including analyses of large linked datasets;

Development economics, she has undertaken research in Ghana, Uganda, Papua New Guinea, India, Indonesia and Solomon Islands;

Preference elicitation using discrete choice experiments; and Qualitative analyses of interviews and focus groups.

Prior to joining Monash in 2010, Paula held a number of lectureship posts in the UK, at the Universities of Nottingham, East Anglia and Glasgow. She holds a PhD in Economics from the University of Otago, New Zealand, and a BSc(Hons) in Economics from the University of Canterbury, New Zealand.

26

Dr. Dinesh Pendharkar, Head of Medical Oncology at Sarvodaya cancer Institute. Immediate past Chair International Affairs Committee ASCO. President Indian Society of Oncology. Was instrumental in establishing specialty of medical oncology in India. Presently mentor to governments of four states. Involved in creating a unique healthcare delivery model for increasing access to cancer care, established across 125 districts in India with coverage to 210 million population.

This involves training physicians from the district, giving them continuous education, offering 24x7 backup and visiting these districts as part of education and system establishment. Extensively involved in International Oncology scenario with training/mentoring activities in multiple countries-Armenia(visisting professor state medical university), Uzbekistan (Consultant national cancer center), Nepal, Bangladesh, Kenya. My vision- professional empowerment in oncology with advocacy at federal level can only solve the challenge of cancer.

Dr. Fred Sun has had a diverse career in health care beginning as a cardiothoracic surgeon at Pennsylvania State University Hershey Medical Center, As Assistant to Department Director of Cardiothoracic surgery at Susquehanna hospital system in Pennsylvania, he co-created systems for quality and safety based on the integration of IT solutions with evidence-based practice, educational systems and advanced bench marking. As a member of PSU International, he became the Deputy Director of International Collaboration Quality and Safety bringing quality and safety into a highly complex medical delivery system.

He continued his career in international health collaboration and healthcare investments, merger and acquisitions in various leading positions for multiple major healthcare enterprises in China

Dr. Sun focus is on the integration of physician leaders into healthcare quality structures under international collaborations.

27

Pennie Taylor is an award-winning freelance journalist and broadcaster who specialises in health and care issues. Based in Glasgow, she was BBC Scotland’s first Health Correspondent and has also worked on the newsdesks of a number of national newspapers. A former Head of Communications for the Lothian University Hospitals NHS Trust in Edinburgh, Pennie has inside knowledge of how public services work. This gives her a uniquely informed perspective from which to approach and stimulate debate.

Dr. Tricia Woodhead, BM, MBA, FRCR Health Foundation Quality Improvement Fellow Tricia is a Health Foundation Quality Improvement Fellow, Associate Clinical Director for Patient Safety the West of England Academic Health Science Network, Visiting Senior Research Fellow at the University of Bath and Person-centred Care Expert with the International Society for Quality in Healthcare. Tricia spent 24 years as a Consultant Radiologist in the NHS combining consultant role with that of Medical Director.

Her current work includes the design and delivery regional and national improvement collaboratives, supporting Royal Colleges in their Leadership offerings and developing on-line courses in Quality Improvement and Leadership with the University of Bath.

Ashley Woolmore is Senior Vice President and Head of European Data and Evidence Networks for IQVIA (formerly Quintiles and IMS Health). Dr Woolmore takes the lead for IQVIA on its major investment projects in European real-world data and evidence networks. He is the Chair of the Collaboration Board and overall lead for the Collaboration for Oncology Data in Europe (www.code-cancer.com). His driving interest is the development of systematic approaches to realise the potential of real-world data for transforming healthcare delivery and treatment outcomes. He is particularly focussed on cancer and its treatment, real-world data and evidence policy topics and

28

innovative approaches to build and enable collaborative networks. Over the last 15 years he has led work on the creation and analysis of large datasets to drive insight into oncology and cancer care, survivorship, the impact of multiple morbidities, palliative care, and chronic disease management. Prior to joining IMS Health (now IQVIA) in 2013, Ashley worked in strategy consulting and was a Partner firstly at Monitor Group, then Deloitte. At the beginning of his career, he trained and practised as a Clinical Psychologist before moving into hospital management and service development within the UK NHS. Ashley now lives with his family in France.

Dr. Jamal Zekri has received his higher medical oncology training in Weston Park Hospital (Sheffield, England). He practiced as a consultant medical oncologist at Clatterbridge Centre for Oncology (Merseyside, England) until April 2008. Currently, he is an associate professor at Al Faisal University and the head of medical oncology services at King Faisal Specialist Hospital & Research Centre (Jeddah, Saudi Arabia). He has published more than 50 papers in peer reviewed journals and presented more than 30 abstracts of original research wok at international conferences.

29

SPONSORS

30